A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Trelagliptin Succinate Monotherapy for Type 2 Diabetes
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Trelagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors CSPC ZhongQi Pharmaceutical Technology
Most Recent Events
- 09 Jan 2021 Status changed from active, no longer recruiting to completed.
- 29 Jun 2020 Status changed from recruiting to active, no longer recruiting.
- 15 May 2019 New trial record